Press coverage about Signal Genetics (NASDAQ:MGEN) has been trending positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Signal Genetics earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.5914083637469 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of research analysts have recently issued reports on the company. Chardan Capital reiterated a “buy” rating on shares of Signal Genetics in a report on Monday, August 7th. Wedbush reiterated a “buy” rating on shares of Signal Genetics in a report on Friday, August 18th. Zacks Investment Research upgraded Signal Genetics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Tuesday, August 15th. Finally, ValuEngine downgraded Signal Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, August 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $18.67.
Shares of Signal Genetics (NASDAQ:MGEN) traded up 2.92% on Friday, hitting $8.29. The stock had a trading volume of 91,959 shares. The stock has a 50 day moving average of $9.15 and a 200 day moving average of $10.96. Signal Genetics has a 12-month low of $0.12 and a 12-month high of $18.00. The firm’s market cap is $178.09 million.
Signal Genetics (NASDAQ:MGEN) last announced its quarterly earnings data on Friday, August 11th. The medical research company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13. Signal Genetics had a negative net margin of 770.31% and a negative return on equity of 92.62%. The business had revenue of $0.72 million during the quarter, compared to the consensus estimate of $0.46 million. Equities analysts predict that Signal Genetics will post ($1.52) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Signal Genetics (NASDAQ:MGEN) Receives Media Sentiment Score of 0.26” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/positive-press-coverage-somewhat-unlikely-to-affect-signal-genetics-mgen-share-price.html.
About Signal Genetics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Signal Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.